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Abstract
Background: Vaccine-associated paralytic poliomyelitis (VAPP) and immunodeficient long-term polio excretors
constitute a significant public health burden and are a major concern for the WHO global polio eradication
endgame.
Case presentation: Poliovirus type 3 characterized as Sabin-like was isolated from a 5-month-old Albanian child
with X-linked agammaglobulinemia and VAPP after oral polio vaccine administration. Diagnostic workup and
treatment were performed in Italy. Poliovirus replicated in the gut for 7 months. The 5’ non coding region (NCR),
VP1, VP3 capsid proteins and the 3D polymerase genomic regions of sequential isolates were sequenced. Increasing
accumulation of nucleotide mutations in the VP1 region was detected over time, reaching 1.0 % of genome
variation with respect to the Sabin reference strain, which is the threshold that defines a vaccine-derived poliovirus
(VDPV). We identified mutations in the 5’NCR and VP3 regions that are associated with reversion to neurovirulence.
Despite this, all isolates were characterized as Sabin-like. Several amino acid mutations were identified in the VP1
region, probably involved in growth adaptation and viral persistence in the human gut. Intertypic recombination
with Sabin type 2 polio in the 3D polymerase region, possibly associated with increased virus transmissibility, was
found in all isolates. Gamma-globulin replacement therapy led to viral clearance and neurological improvement,
preventing the occurrence of persistent immunodeficiency-related VDPV.
Conclusions: This is the first case of VAPP in an immunodeficient child detected in Albania through the Acute
Flaccid Paralysis surveillance system and the first investigated case of vaccine associated poliomyelitis in Italy since
the introduction of an all-Salk schedule in 2002. We discuss over the biological and clinical implications in the
context of the Global Polio Eradication Program and emphasize on the importance of the Acute Flaccid Paralysis
surveillance.
Keywords: Poliovirus, Oral polio vaccine, Vaccine-associated paralytic poliomyelitis, X-linked agammaglobulinemia,
Acute flaccid paralysis, Vaccine-derived poliovirus
* Correspondence: thomas.foiadelli@gmail.com
1Department of Pediatrics, University of Pavia, Policlinico San Matteo IRCCS
Foundation, Pavia, Italy
Full list of author information is available at the end of the article
© 2016 Foiadelli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Foiadelli et al. BMC Infectious Diseases  (2016) 16:277 
DOI 10.1186/s12879-016-1587-y
Background
In 1988, the World Health Assembly launched the Glo-
bal Polio Eradication Initiative. Live attenuated oral
poliovirus vaccine (OPV) was selected by WHO for rou-
tine use and national immunization days. OPV might re-
quire several doses to induce immunity, but then it
provides long-term protection against paralytic disease
through durable humoral and mucosal immunity [1].
The use of OPV, however, is associated with some rare
adverse events, including the occurrence of vaccine-
associated paralytic poliomyelitis (VAPP) [2] and the
emergence of vaccine-derived polioviruses (VDPVs) [3].
VAPP occurs at very low rates (∼1 case per 600,000 first-
dose recipients) [4], and it is estimated that approxi-
mately 498 (range 255–1018) VAPP cases occur world-
wide each year [2]. VAPP risk is 3000–7000 fold higher
in persons with primary immunodeficiencies, notably
agamma- and hypogammaglobulinemia, exposed to
OPV [5]. In a small proportion of immunodeficient pa-
tients, Sabin strains can replicate in the intestine for sev-
eral months or years [6–8], in contrast to the short
(typically 3–4 weeks) period of replication in immuno-
competent persons following their first OPV dose [9].
Because the poliovirus genome typically evolves at an
average rate of 1 % per year, prolonged replication or cir-
culation of viruses derived from OPV is recognized by
the accumulation of genomic nucleotide substitutions
[6]. VDPVs are operationally defined as vaccine-related
isolates having >1 % nucleotide divergence from the cor-
responding type 3 or type 1 Sabin strain in the genome
coding for the major capsid surface protein, VP1 (or
>0.6 % in case of type 2 polioviruses). By contrast, OPV-
like isolates have limited divergence from their parental
OPV strains and are ubiquitous wherever OPV is used.
The occurrence of immunodeficiency-related-VDPV
(iVDPV) is typically consistent with at least 1 year of
poliovirus replication since the administration of the first
OPV dose. Nevertheless, evolution rates as fast as 2 %/
year have been observed in the early phases of patients
with iVDPV [10]. Since the introduction of OPV in
1961, more than 70 subjects with primary immunodefi-
ciencies have been found excreting iVDPVs worldwide;
the majority of these immunodeficiencies were detected
after the onset of VAPP [1]. Type 2 iVDPVs are the most
prevalent (64 %), followed by type 1 (21 %) and type 3
(15 %) [1]. By contrast, VAPP in immunocompetent
OPV recipients and household contacts is most fre-
quently associated with type 3 (71 %) followed by type 2
(26 %) poliovirus [5, 6].
Albania is considered polio free since 1997. The last
polio outbreak of 1996 was caused by an imported wild
type 1 poliovirus. Vaccination with OPV was maintained
until March 2014, when a sequential schedule using
inactivated polio vaccine (IPV) followed by OPV was
adopted. The Acute Flaccid Paralysis (AFP) surveillance,
established in 1997, has always met the WHO standard
performance: two VAPP cases were detected until now,
both affecting immunocompetent children after the first
OPV dose [4].
Italy is considered polio-free since 1982, when the last
indigenous wild polio cases occurred. Three imported
wild polio cases from Iran, India and Libya (the last in
1988) were reported afterwards [11]. Since then, only
rare VAPP cases (two of which were household contacts)
have occurred in Italy [12, 13] before the adoption of
Salk vaccine (IPV) in 2002 [14, 15]. The last VAPP case
in Italy occurred in the year 2000 in a one-year old im-
munodeficient child who received three doses of OPV
[16] and was detected through the AFP surveillance in
force in Italy since 1997 according to the WHO guide-
lines [17].
We report the case of an Albanian infant affected by
congenital agammaglobulinemia, who developed VAPP
at the age of 5 months after receiving two doses of OPV
in his country, and was then referred to Italy for further
treatment. We isolated from sequential stool samples
Sabin-like type 3 polioviruses, which accumulated 1 % of
mutations in the VP1 viral genome in 7 months. We
herein describe the genetic evolution of the poliovirus
during the entire period of excretion, and discuss the
implications of chronic virus excretion for the global
polio eradication strategy.
This is the first case of VAPP in immunodeficient child
detected in Albania through the AFP Surveillance sys-
tem and the first iVDPV case investigated in Italy since
the occurrence of the indigenous iVDPV case reported
by Buttinelli and colleagues in 2003 [16].
Case presentation
Case report
XY, male, was born in Albania after a normal delivery
from non-consanguineous parents in December 2013.
The patient was vaccinated following the local schedule
with bacille Calmette-Guérin (BCG) and hepatitis B vac-
cine at birth, and with pentavalent vaccine (diphtheria,
pertussis, tetanus, hepatitis B and Haemophilus influen-
zae type b), 10-valent pneumococcal conjugate vaccine
and trivalent OPV at the age of 2 and 4 moths. On June
2014, at the age of 5 months, he was hospitalized in
Tirana University Hospital for the occurrence of acute
flaccid quadriplegia with left facial paralysis and respira-
tory distress, 10 days after a self-limiting febrile enteritis.
Blood investigations and C-reactive protein were normal.
Cerebrospinal fluid (CSF) analysis demonstrated hyper-
cellularity (196 cells/μL, 95 % lymphocytes), normal glu-
cose concentration (53 mg/dl) and high proteinorrachia
(100 mg/dl). CSF Gram stain and bacterial culture, and
serology for Herpes Simplex type 1 and 2 were negative
Foiadelli et al. BMC Infectious Diseases  (2016) 16:277 Page 2 of 10
for recent infection. Cerebral magnetic-resonance im-
aging was normal. Electroneurography was consistent
with axonal motor neuropathy. In the suspect of an in-
flammatory meningo-radiculitis, polyclonal intravenous
immunoglobulins (IVIG) at the dose of 1 g/kg/day for
two days were started, along with acyclovir and cefotax-
ime, followed by prompt respiratory function improve-
ment. According to the AFP surveillance program, stools
samples were collected and sent to the WHO National
Polio Reference Laboratory in Tirana (Albania). This led
to the isolation and identification of type 3 poliovirus,
later characterized as Sabin-like by the WHO Regional
Polio Reference Laboratory in Rome, Italy. Serum im-
munoglobulin levels after IVIG administration, were:
IgG 1060 mg/dl (normal values 470–1230), IgA
<6.7 mg/dl (normal values 21–145), IgM 5.7 mg/dl (nor-
mal values 47–175).
On July 2014, the patient was admitted to the Pediatric
Clinic of San Matteo Hospital in Pavia (Italy) for further
evaluation. Neurological assessment evidenced flaccid
paralysis of the left lower limb and paresis of the right
upper and lower limbs. Electroneurography (ENG)
assessing motor and sensory nerve conduction and nee-
dle electromyography (EMG) was performed in proximal
and distal muscles of upper and lower affected limbs,
using Medelec Synergy EMG equipment (band-pass fil-
ter: 10–10,000 Hz) at the National Neurological Institute
C. Mondino (Pavia, Italy). Findings were consistent with
axonal motor neuropathy and muscular active denerv-
ation, with severe neurogenic signs, mainly at the right
upper and left lower limbs (Fig. 1a and c). Immuno-
logical assessment proved absence of circulating B cells
and inadequate immunoglobulin production after in
vitro lymphocyte stimulation, with normal count and
function of T lymphocyte subsets. These findings were
consistent with vaccine-associated poliomyelitis in a pa-
tient with X-linked agammaglobulinemia. The congenital
defect was confirmed by reduced in vitro expression of
the BTK protein in blood leukocyte populations, and the
identification of a causative de novo mutation [1922G >
A] of the BTK gene. IVIG substitution therapy was
started at 400 mg/kg/dose for 7 days and every three
weeks thereafter, with strict serum immunoglobulins
monitoring.
All hygienic precautions for the possible spread of the
virus were taken, according to the Centers for Disease
Control and Prevention (CDC) guidelines for isolation
precautions (2007) [18]. All the hospitalized patients in
the Pediatric Unit at this time were vaccinated with ei-
ther IPV or with OPV according to their vaccination
schedules. We alerted all medical and non-medical staff,
as well as the patient’s parents, to the potential risk for
virus transmission. A physiotherapy program was
started, and the child was discharged with signs of mild
neurological improvement. The residual paralysis of the
upper and lower limbs significantly improved with ad-
equate physiotherapy at 1-year follow up. ENG/EMG
performed on August 2015, 13 months after baseline,
showed recovery of motor nerve conduction amplitudes
and signs of muscular reinnervations (Figs. 1 and 2).
Electroneurographic changes consistent with axonal re-
generation are evidenced in Table 3.
The child’s parents expressed informed written con-
sent for publication of all clinical data.
Virus isolation and typing
Stools from the patient were processed according to the
Polio Laboratory Manual, WHO [19] inoculating 0.5 ml
of the 10 ml chloroform-extracted samples onto two RD
and two L20B (selective for polioviruses) cell monolayers
in 50 ml cell culture flasks. Samples negative at first iso-
lation underwent two serial blind passages in both cell
lines, and samples positive on RD cells were passaged on
L20B for specific amplification of poliovirus. Stool speci-
mens collected in June in Albania were processed at the
WHO National Polio Reference Laboratory in Tirana
(NRL); stools samples collected in Italy in July, Septem-
ber and thereafter were analysed at the WHO Regional
Polio Reference Laboratory in Rome (RRL). Polio typing
at the NRL was performed by monospecific anti-PV
pooled sera RIVM/WHO kit (National Institute of Pub-
lic Health and Environment, RIVM, Bilthoven,
Netherlands in accordance with the WHO protocol)
[19]. Typing at the RRL was obtained by real time re-
verse transcription PCR (rRT-PCR) with specific primers
(CDC) [19].
Intratypic differentiation and genome sequencing
Intratypic differentiation (ITD) between Sabin-like or
non-Sabin-like polioviruses was performed by rRT-
PCR with specific primers (CDC) [19]. Sequencing of
the 5’NCR (nt 179 to 575), VP1 (nt 2479 to 3378),
VP3 (nt 1948–2146) and 3D (nt 6134 to 6353) gen-
omic regions, following rRT-PCR amplification, was
performed for all type 3 polioviruses isolates: two
from Albania (A1 and A2 June) and 4 from Italy (B1
and B2 July, C1 and C2 September) (Table 1). The
ITD and sequencing of all strains were performed at
the WHO Regional Polio Reference Laboratory in
Rome, Italy.
The amplified sequences of the 5’NCR, VP1, VP3 and
3D region were analyzed using sequencing software. The
percentage of identity was determined on the number of
nucleotide substitutions per site with respect to the ref-
erence Sabin type 3 strain. Amino acid sequence align-
ments were obtained using the software Sequencer [20].
Nucleotide sequence accession numbers for the refer-
ence Sabin type 3 and type 2 were AY184221.1 and
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AY184220. The nucleotide sequences of the 5’NCR,
VP1, VP3 and 3D regions of polioviruses have been de-
posited in the GenBank database (accession numbers:
KU708511-KU708514). We used the program Phyre2 to
localize in the three-dimensional structure of the type 3
poliovirus the amino acid substitutions found in the cap-
sid proteins [21].
Neutralization assay
Serum samples were tested for their neutralizing activity
against the three poliovirus serotypes at the RRL, Rome.
Two fold dilutions of sera were incubated with equal
volumes of Eagle’s MEM containing 100 TCID50 (tissue
culture infectious dose) of Sabin poliovirus (types 1, 2
and 3). Plates were scored for cytopathic effect (CPE) on
the third, fifth and seventh day. Neutralization titers
were defined as the reciprocal of the highest dilution of
serum yielding a 50 % reduction of CPE [22]. Seroposi-




Type 3 polioviruses (PV3) were isolated from the first
stool specimens (A1 and A2 June) collected in Albania
and from stools samples (B1 and B2 July) and (C1 and
C2 September) collected in Italy at S. Matteo Hospital.
Stools collected thereafter were negative for poliovirus
replication after three blind passages on L20B and RD
cells cultures (Table 1). No other poliovirus or non-polio
enteroviruses were isolated.
Fig. 1 Electroneurography changes at baseline and after 1-year of follow-up. Electroneurography of the right ulnar (a-b) and left peroneal (c-d)
nerves at the time of hospitalization in Italy (July 2014) (a-c) and at the 1-year follow-up (August 2015) (b-d). Notice the improvement of the
composite motor action potentials (CMAP) amplitude in both the examined upper and lower limbs, which is consistent with axon regeneration
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Characterization of polio type 3 isolates and genomic
analysis
All PV3 strains were characterized as Sabin-like by ITD.
In order to study the genome evolution during replica-
tion, the RNA of six sequential strains (A1, A2, B1, B2,
C1 and C2) was analyzed by nucleotide sequencing. The
nucleotide differences of the strains with respect to the
PV3 Sabin reference evidenced for all isolates a reversion
(U > C) at position 472 of the 5’NCR in the domain V of
the internal ribosome entry site (IRES). This mutation is
known to occur very rapidly upon replication of the
virus in the human gut, and plays an important role in
the attenuated phenotype of poliovirus type 3 [23–25].
An additional mutation was found in all strains in the
5’NCR at nucleotide (nt) 292 (G > A), in the domain IV
of the IRES. These mutations have been described in
other PV3 and VDPVs isolates from immunodeficient
patients [24, 26–28]. The mutations identified in the re-
gion that codes for the major capsid protein VP1 (nt
2477–3376) with respect to Sabin type 3 are reported in
Table 2. In the first isolate (A1 June), mutations were lo-
cated at position 150 (C > T), 161 (C > T) generating an
amino acid substitution at amino acid (aa) 54 (Ala > Val),
and at position 336 (T > C), 417 (C > T) and 846 (G > A).
In the second isolate (A2 June), two additional muta-
tions were found at position 192 (A > G) and 193 (G >
A), this last one generating a replacement (Val > Ile) at
aa 65. The isolate (B1 July) collected in Italy presented
two further mutations at position 314 (T > C), which
leads to an amino acid replacement at aa 105 (Met > Thr),
Table 1 Collected samples and cell culture isolation
Specimen Origin Collection date RDa L20Bb
A ALBANIA A1 11-06-14 A2 13-06-14 Positive (PV3) Positive (PV3)
B ITALY B1 18-07-14 B2 21-07-14 Positive (PV3) Positive (PV3)
C ITALY C1 11-09-14 C2 12-09-14 Positive (PV3) Positive (PV3)
D ITALY D1 24-09-14 D2 24-09-14 Negative (3rd passage) Negative (3rd passage)
E ITALY E1 24-10-14 E2 24-10-14 Negative (3rd passage) Negative (3rd passage)
F ITALY F1 24-11-14 F2 24-11-14 Negative (3rd passage) Negative (3rd passage)
G ITALY G1 16-12-14 G2 17-12-14 Negative (3rd passage) Negative (3rd passage)
H ITALY H1 14-01-15 H2 14-01-15 Negative (3rd passage) Negative (3rd passage)
Specimens A to H refer to the sequential collection of different stool samples from the immunodeficient patient. Type 3 poliovirus (PV3) was isolated from the
first stool specimens (A1, A2) collected in Albania in June 2014, and from four stool samples collected in Italy until September 2014 (B1, B2, C1 and C2)
a RD, Rhabdomyosarcoma cell line
b L20B, Recombinant murine cell line specific for polioviruses
Fig. 2 Electromyography traces of improved voluntary activity in the left lower limb at 1-year follow-up (August 2015). Signs of collateral motor
reinnervation and axon regeneration in both the left vastus lateralis and tibialis anterior
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and at position 774 (T > C). All nucleotide mutations and
amino acid substitutions found in (B1 July) persisted dur-
ing the entire period of excretion without further changes.
The evolution rate, expressed as a percentage of
changes with respect to Sabin type 3, was rather con-
stant during the excretion period, increasing from 0.5 %
in the first isolate to 1 % in the last isolate (Table 2).
This corresponds approximately to 1–2 changes per
week. The sequencing of the VP3 region revealed in all
PV3 isolates a mutation at nt 273 (T > C) causing an
amino acid substitution at position 91 (Phe > Ser). This
mutation is involved in the capsid assembly and is
known to be correlated with the neurovirulent pheno-
type in type 3 polioviruses [29, 30]. The sequential
amino acid substitutions in VP1 and VP3 mapped onto
the three-dimensional X-ray crystallographic atomic co-
ordinates of Sabin type 3 are shown in Fig. 3.
The sequencing of the 3D polymerase-coding region
revealed an intertypic recombination Sabin 3/Sabin 2 in
all isolated strains. The Sabin 2 genome encompassed
the entire 3D region and no mutation was found with
respect to the reference Sabin 2.
Neutralizing antibodies
The two sera collected in September and December
2014 at San Matteo Hospital in Pavia had passive neu-
tralizing antibody titers against all three PV: sample (C
September) had a titer of 1:32 for PV1, 1:91 for PV2 and
1:91 for PV3, sample (G December) had a titer of 1:23
for PV1, 1:32 for PV2 and 1:64 for PV3. The WHO con-
siders as protective a titer >1:8 [31].
Conclusions
Sabin OPV vaccine has been adopted by the WHO for
the Global Polio Eradication Initiative (GPEI) and de-
cades of experience have shown that it is safe and effect-
ive in preventing poliomyelitis. However, it is known
that attenuated viruses may revert to neurovirulent
Table 2 Nucleotide and amino acid variation in the VP1 region
11/06/2014 ALB (A1) 13/06/2014 ALB (A2) 18/07/2014 ITA (B1) 21/07/2014 ITA (B2) 11/09/2014 ITA (C1) 12/09/2014 ITA (C2)
NT AA NT AA NT AA NT AA NT AA NT AA
150 C > T 150 C > T 150 C > T 150 C > T 150 C > T 150 C > T
161 C > T 54 A > V 161 C > T 54 A > V 161 C > T 54 A > V 161 C > T 54 A > V 161 C > T 54 A > V 161 C > T 54 A > V
192 A > G 192 A > G 192 A > G 192 A > G 192 A > G
193 G > A 65 V > I 193 G > A 65 V > I 193 G > A 65 V > I 193 G > A 65 V > I 193 G > A 65 V > I
314 T > C 105 M > T 314 T > C 105 M > T 314 T > C 105 M > T 314 T > C 105 M > T
336 T > C 336 T > C 336 T > C 336 T > C 336 T > C 336 T > C
417 C > T 417 C > T 417 C > T 417 C > T 417 C > T 417 C > T
774 T > C 774 T > C 774 T > C 774 T > C
846 G > A 846 G > A 846 G > A 846 G > A 846 G > A 846 G > A
Nucleotide substitutions and the relative amino acid changes in the VP1 capsid region, in sequential isolates during the excretion period
NT nucleotide, AA amino acid
Fig. 3 Ribbon diagram of the α-carbon trace of the Sabin type 3.
Complete frontal view of the VP1-VP4 capsid proteins. Amino acid
substitutions in the capsid proteins VP1 and VP3 found in the iso-
lated poliovirus type 3 are highlighted
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phenotypes upon replication in the human gut, rarely
causing VAPP in immunocompetent individuals [2]. Im-
munodeficient persons vaccinated with OPV have a
3000–7000 time higher risk of developing VAPP, espe-
cially when affected by agammaglobulinemia or hypo-
gammaglobulinemia [32]. Moreover, in immunodeficient
subjects attenuated OPV viruses replicate in the gut and
can persist for long periods [15, 33–35]. Excreted viruses
rapidly accumulate mutations and genetic rearrange-
ments, increasing the chance of reversion to neuroviru-
lence and transmissibility. For these reasons, long-term
excretors of poliovirus and immunodeficient patients are
an additional concern for the WHO, as they could con-
stitute a polio reservoir in the post-eradication era, and
infect both unvaccinated and immunocompromised per-
sons [8, 36, 37].
In this work, we report a detailed molecular analysis of
six sequential type 3 polioviruses isolated from an Alba-
nian child affected by congenital agammaglobulinemia
who developed flaccid paralysis 1 month after receiving
the second dose of OPV in his country. The ITD of the
strains confirmed the Sabin-like characteristic of all PV3
isolates.
In middle- and high-income countries, VAPP occurs
more frequently after receiving the first dose of OPV
and can affect unvaccinated contacts. Poliovirus type 2
(Sabin or iVDPV) is the prevalent isolated serotype in
immunodeficient individuals, while type 3 only counts
for 15–32 % of isolations [1, 2, 38]. Our patient devel-
oped VAPP after receiving the second dose of OPV, at
the age of 5 months. Interestingly, he had been breastfed
during the first 4.5 months of life. Enteroviruses are
cleared from the host mainly by antibody-mediated
mechanisms. Secretory IgA can neutralize viruses by rec-
ognizing specific capsid antigens, reducing infectivity
and promoting viral clearance [39, 40]. The patient’s
mother had been vaccinated with OPV, which stimulates
durable mucosal immunity through IgA secretion. We
speculate that passive transfer of maternal IgA via
breast-feeding could have played a role in limiting virus
proliferation in the gut of our patient after the first dose
of OPV. It is also known that the presence of anti-polio
antibodies in the blood prevents the central nervous sys-
tem (CNS) invasion [41]. In our case, we can assume
that the physiological postnatal decreasing of maternal
antibodies, associated with breast-feeding interruption in
the absence of self secretory-IgA, led to a rapid viral rep-
lication in the gut, and subsequently invasion of the
CNS, causing VAPP at the age of 5 months.
After the first virus isolation in Albania in June, stool
samples were monthly collected during his
hospitalization in Italy and analyzed by the WHO RRL
for polio in Rome to verify poliovirus persistence and
genetic evolution. In all samples collected until
September 2014 (ALB A1, A2, and ITA B1, B2, C1, C2)
a poliovirus type 3 was isolated. Samples collected there-
after were negative for polio and other enteroviruses
(Table 1). This reveals, in contrast with other reported
cases [24, 34], a quick clearance of poliovirus in our pa-
tient, with a complete eradication after 3 months of
IVIG administration. Therapy was well tolerated, with-
out side effects, and led to objective clinical and neuro-
physiological improvement (Table 3). No antivirals were
administered in our case. The rapid clearance of the
virus in this subject is likely due to the timely adminis-
tration of IVIG at high doses with strict IgG concentra-
tion monitoring (compared to the less useful monthly
administration of fresh frozen plasma therapy [24] or
IVIG at lower doses [27]). A further explanation could
be the presence of high antibody titers against type 3 in
the specific sera used for the replacement therapy that
would allow a better neutralization. However, there’s still
little knowledge on IVIG use in VAPP, possibly because
most of the cases have been reported in the past, before
the availability of polyclonal injectable immunoglobulins,
and recently only in low-income countries where IVIG
are too expensive or still not available.
The lack of isolation of poliovirus type 1 or 2 Sabin-
like strains might be related to reduced replication of
these serotypes in the human gut. We can nonetheless
hypothesize a greater passive protection against these
two serotypes conferred by maternal antibodies.
Sequencing of the 5’NCR and VP3 regions evidenced a
U > C mutation at nt 472 in the domain V of the IRES
and at the amino acid residue 91 (Phe > Ser): both cor-
relate in PV3 with reversion of the attenuated pheno-
type, confirming their importance for neurovirulence
and possibly for adaptation and replication in the gut
[24, 25, 40]. The additional mutation in 5’NCR nt 292
(G > A) in the domain IV of the IRES was also found in
other PV3 isolated from iVDPV and VAPP cases [24, 25]
but its role in conferring neurovirulence has not been
demonstrated. Mutations in VP1 quickly increased over
time reaching 1 % genome variation in the samples (ITA
C1 and C2) collected in September 2014. The strains
were still Sabin-like, but the percentage of accumulated
nucleotide mutations was very close to the value >1 %
that defines an iVDPV.
Viruses replicating in immunodeficient patients tend
to select characteristic mutations at different times dur-
ing the infection, suggesting that specific selection pres-
sures may operate in the gut over time. The amino acid
substitutions at position 105 (Met > Thr) and 54 (Ala >
Val) of VP1 have already been described by Martin and
colleagues in a PV3 strain isolated from an immunodefi-
cient patient [24]. Amino acid VP1 105 is located at the
north rim of the canyon in the hydrophobic pocket, and
plays a role for the uncoating of the virus. The
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substitution 54 (Ala > Val) in VP1 acts as a suppressor of
the temperature sensitivity and attenuation phenotype
(the capacity of growth at elevated temperatures is in-
deed typical of wild poliovirus strains) [42]. Other muta-
tions that are known to be involved in growth
adaptation, viral persistence and increased neuroviru-
lence, such as sequence variation at nucleotide 2493 in
VP1[43, 44], were not found in our patient.
Finally, sequencing of the 3D polymerase revealed the
presence of an intertypic recombination with type 2 Sa-
bin (recombinant PV3/PV2 Sabin) in all isolates. This is
an interesting finding, even though similar recombina-
tions have already been described in healthy vaccinees,
iVDPV and VAPP cases [33, 45].
The global prevalence of immunodeficient subjects
with chronic polio infection is unknown and if asymp-
tomatic they remain undetected. This poses a risk in the
context of the GPEI endgame. Therefore, the detection
of chronic iVDPV excretors in all countries and the de-
velopment of antivirals to eradicate chronic infections is
a WHO priority. Sequence properties of circulating
VDPV (cVDPV) strains are distinguishable from iVDPV
strains excreted by chronic infected persons. The com-
parison between the mutational patterns found in
iVDPV and cVDPV can predict the origin of the anoni-
mous VDPV (aVDPV) strains isolated during the envir-
onmental surveillance. This remains crucial for
epidemiological interpretation because it may alert for
the presence of a chronic iVDPV excretor in the com-
munity [3]. Environmental surveillance will be imple-
mented by the GPEI in low income countries since it
proved to be very sensitive in detecting cVDPV and
iVDPV strains [46]. In this sense the mutations found in
our study can add knowledge to the definition of
iVDPVs genetic pattern.
OPV plays a key role in the eradication of wild polio-
virus and is still used in regions where wild poliovirus is
not definitively eradicated or with high risk of polio
outbreak. Occurrence of cVDPV outbreaks and iVDPV
cases and the potential spread of highly neurovirulent
poliovirus strains to the environment has recently led
the WHO to state that OPV usage will globally be dis-
continued soon after the certification of global eradica-
tion [3, 6, 24]. The endgame plans for the GPEI actually
include the synchronic replacement of the trivalent Sa-
bin live-attenuated oral poliovaccine (tOPV) with the bi-
valent bOPV (PV1,3) as a first step to prevent the more
frequent cVDPV type 2 outbreaks. The subsequent with-
drawal of all OPV use and the maintenance of high
immunization coverages with IPV will protect against
imported wild polioviruses and prevent cVDPV out-
breaks and new iVDPV infections [47]. As Albania did
in 2014, most low income countries are incorporating at
least 1 dose of IPV into routine childhood immunization
schedules. The production of less expensive inactivated
Salk IPV vaccine based on the Sabin strains vaccines is
encouraged by the WHO for environmental safety and a
large-scale use [47]. Because many high-income coun-
tries have replaced OPV with IPV, the VAPP burden is
currently concentrated in lower-income countries. The
planned universal introduction of IPV will also substan-
tially decrease the global VAPP cases [2]. However, it is
important that all countries maintain high quality of
AFP surveillance and improve the current laboratory
typing methods to better differentiate between VDPVs
and wild poliovirus strains.
This is the first case of poliomyelitis and long-term ex-
cretion from an immunodeficient patient detected in
Albania through the Acute Flaccid Paralysis surveillance
system. Due to the high levels of immigration across the
Mediterranean sea, Italy, Albania and other Mediterra-
nean countries remain at risk of importing wild polio-
virus from endemic areas as well as Sabin and
neurovirulent VDPVs from countries currently using
OPV. Moreover, since IPV vaccine (adopted in Italy
since 2002) may not elicit a consistent mucosal
Table 3 Electroneurographic values at baseline and at the 1-year follow-up
Nerve July 2014 August 2015
Latency (ms) Amplitude (mV) Velocity (m/s) Latency (ms) Amplitude (mV) Velocity (m/s)
Right ULNAR
1. Wrist 2,00 0,9 2,20 4,5
2. Elbow 4,90 0,9 39,7 4,20 3,8 62,5
Right MEDIAN
1. Wrist 3,05 1,4 2,90 1,0
2. Elbow 5,30 0,7 40,0 5,70 1,2 41,1
Left COMMON PERONEAL
1. Ankle 2,40 1,2 2,75 1,9
2. Fibular Head 5,05 0,8 41,5 5,30 2,1 47,1
Comparison of the electroneurographic values at the time of hospitalization in Italy (July 2014) and after 1 year (August 2015) with evidence of significant
improvement in the motor potentials amplitude of both the examined upper and lower limbs
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immunity, silent transmission of neurovirulent poliovirus
might occur through IPV-immunized individuals,
favouring possible infection of unvaccinated subjects or
children receiving delayed vaccination [22, 48, 49]. For
these reasons an Active AFP surveillance is in force at
national level as well as an environmental surveillance in
seven large Italian cities with high immigration rate [45].
Immunodeficient patients have been monitored for sev-
eral years in Italy and no poliovirus long-term excretors
have been detected [50]. In Albania this screening has
not been performed, but in the future environmental
surveillance and monitoring of immunodeficient persons
will be implemented.
No antivirals are currently available to interrupt polio-
virus excretion in immunodeficient subjects. The capsid-
binding drug pleconaril that prevents poliovirus cell-
entry has been tried in a reported case by our group
with successful interruption of viral excretion when
combined with IVIG treatment [16]. Developing effect-
ive drugs/treatments is a WHO priority and research is
ongoing in this field.
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